Q32 Bio

Recent Finacing

Series B

Recent Raise

$60M

Q32 Bio is a clinical-stage biotech in Cambridge developing biologic therapeutics to restore immune regulation via an anti-IL-7R monoclonal antibody (ADX-914) and tissue-targeted complement fusion proteins (ADX-097).

Founded 2017

Massachusetts, United States

11-50

Publicly Traded

q32bio.com

Highlights

Focus Areas

Biotechnology

Health Care

Medical

Therapeutics

Recent Investors

Financials

$106M

Total Raised

2

Funding rounds

8

Investors

Team

Upgrade to view the team

See the team members at Q32 Bio.